Literature DB >> 12370466

Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange.

Yang Mao-Draayer1, Steven Braff, William Pendlebury, Hillel Panitch.   

Abstract

The authors describe a patient with an isolated, gadolinium-enhancing, biopsy-proven focus of tumefactive demyelination. There was marked clinical improvement with plasma exchange after failure of high-dose i.v. corticosteroids. The post-treatment clinical course correlated with decreasing enhancement and lesion size on MRI. This patient's rapid clinical and MRI response suggests that plasma exchange may be beneficial in this disorder, and could perhaps serve as a diagnostic tool to avoid the need for brain biopsy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12370466     DOI: 10.1212/wnl.59.7.1074

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  Recurrent tumefactive demyelination without evidence of multiple sclerosis or brain tumour.

Authors:  A Häne; M Bargetzi; E Hewer; M Bruehlmeier; A Khamis; U Roelcke
Journal:  J Neurol       Date:  2010-08-29       Impact factor: 4.849

2.  Case Series: tumefactive demyelinating lesions: a diagnostic challenge.

Authors:  Aria Fallah; Sarfaraz Banglawala; Shanil Ebrahim; John E Paulseth; Neilank K Jha
Journal:  Can J Surg       Date:  2010-02       Impact factor: 2.089

3.  Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis.

Authors:  Kristin M Ikeda; Donald H Lee; J Alexander Fraser; Seyed Mirsattari; Sarah A Morrow
Journal:  Int J MS Care       Date:  2015 Sep-Oct

4.  Beneficial plasma exchange response in central nervous system inflammatory demyelination.

Authors:  Setty M Magaña; B Mark Keegan; Brian G Weinshenker; Bradley J Erickson; Sean J Pittock; Vanda A Lennon; Moses Rodriguez; Kristine Thomsen; Stephen Weigand; Jay Mandrekar; Linda Linbo; Claudia F Lucchinetti
Journal:  Arch Neurol       Date:  2011-03-14

Review 5.  Tumefactive demyelinating lesions: nine cases and a review of the literature.

Authors:  Lei Xia; Song Lin; Zhong-cheng Wang; Shao-wu Li; Li Xu; Jing Wu; Shu-yu Hao; Chuan-chuan Gao
Journal:  Neurosurg Rev       Date:  2009-01-27       Impact factor: 3.042

Review 6.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

Review 7.  [Multiple sclerosis: potential therapeutic options and update of ongoing studies].

Authors:  H Wiendl; H C Lehmann; R Hohlfeld; H-P Hartung; B C Kieseier
Journal:  Nervenarzt       Date:  2004-06       Impact factor: 1.214

Review 8.  Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.

Authors:  Meredith C Frederick; Michelle H Cameron
Journal:  Curr Neurol Neurosci Rep       Date:  2016-03       Impact factor: 5.081

Review 9.  Idiopathic inflammatory-demyelinating diseases of the central nervous system.

Authors:  A Rovira Cañellas; A Rovira Gols; J Río Izquierdo; M Tintoré Subirana; X Montalban Gairin
Journal:  Neuroradiology       Date:  2007-02-28       Impact factor: 2.995

Review 10.  Multiple sclerosis therapy: an update on recently finished trials.

Authors:  Christoph Kleinschnitz; Sven G Meuth; Olaf Stüve; Bernd Kieseier; Heinz Wiendl
Journal:  J Neurol       Date:  2007-11-15       Impact factor: 6.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.